RICHTER'S TRANSFORMATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): ANALYSIS OF BIOLOGICAL AND CLINICAL RISK FACTORS AND OUTCOMES

EHA Library, Edwin Gershom, 53689

INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BENDAMUSTINE/RITUXIMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Kai Riecke, 53690

A SYSTEMATIC REVIEW AND EVIDENCE SYNTHESIS OF RANDOMISED CONTROLLED TRIALS (RCT) FOR THE TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Joan Quigley, 53691

PROSPECTIVE VALIDATION OF A RISK SCORE BASED ON BIOLOGICAL MARKERS FOR PREDICTING PFS IN BINET STAGE A CLL PATIENTS: RESULTS OF THE MULTICENTER O-CLL1-GISL STUDY

EHA Library, Massimo Gentile, 53692

SALVAGE TREATMENT WITH BENDAMUSTINE, OFATUMUMAB, HIGH-DOSE METHYLPREDNISOLONE (BOMP) IN HIGH-RISK R/R CLL : INTERIM RESULTS OF THE FRENCH CLL INTERGROUP (GCFLLC/MW - GOELAMS) ICLL01 PHASE 2 TRIAL.

EHA Library, Olivier TOURNILHAC, 53693

NOVEL GENE MUTATIONS IN CHINESE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

EHA Library, Yi Xia, 53694

THE ROLE OF ALLOGENEIC STEM-CELL TRANSPLANTATION FOR RICHTER'S SYNDROME - META-ANALYSIS

EHA Library, Darko Antic, 53697

BLOOD STREAM INFECTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA: STABLE DISTRIBUTION BUT WITH INCREASED MORTALITY RATE?

EHA Library, Christian Kjellander, 53699

TARGETING OF STAT3 AND STAT5 BY A NOVEL DRUG- COMBINATION EMPLOYING PONATINIB AND BARDOXOLONE METHYL (CDDO-ME) LEADS TO SYNERGISTIC EFFECTS IN BCR/ABL-T315I-MUTATED CELLS IN PH+ CML

EHA Library, Karoline V. Gleixner, 53700

LASP1 IS A NOVEL BCR-ABL SUBSTRATE AND A PHOSPHORYLATION-DEPENDENT BINDING PARTNER OF CRKL IN CHRONIC MYELOID LEUKEMIA

EHA Library, Jochen Frietsch, 53702

MYELOID DERIVED SUPPRESSOR CELLS (MDSCS) AS POTENTIAL IMMUNE ESCAPE MECHANISM IN CML PATIENTS

EHA Library, Cesarina Giallongo, 53704

BIN1 AND RIN1 MODULATION IN CHRONIC MYELOID LEUKEMIA

EHA Library, Stefania Trino, 53705

PROMOTER METHYLATION OF THE TUMOR SUPPRESSOR GENES ON THE SHORT ARM OF CHROMOSOME 1 IN CHRONIC MYELOGENOUS LEUKEMIA

EHA Library, Naoki Mori, 53706

BONE MARROW (BM) MICROENVIROMENT FACTORS AS EARLY MARKERS OF RESPONSE IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP) TREATED WITH NILOTINIB.

EHA Library, Concetta Quintarelli, 53707

IMPACT OF CLONAL EVOLUTION ON THE OVERALL SURVIVAL OF PATIENTS WITH CML TREATED WITH IMATINIB: EXPERIENCE OF ONE CENTER

EHA Library, Kostyantyn KOTLYARCHUK, 53709

A FUNCTIONAL POLYMORPHISM IN THE 3' UNTRANSLATED REGION OF THE ARHGAP26 GENE CONFERS AN INCREASED RISK OF CHRONIC MYELOID LEUKEMIA AND CAUSES ILLEGITIMATE REGULATION BY MICRORNA-18A-3P

EHA Library, Agnieszka Dzikiewicz-Krawczyk, 53710

PHARMACOGENETIC DETERMINANTS OF PLASMATIC AND INTRACELLULAR TYROSINE KINASE INHIBITORS

EHA Library, Carmen Fava, 53711

THE COMBINATION OF PANOBINOSTAT AND PONATINIB EXERTS SYNERGISTIC CYTOTOXICITY IN IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA CELL LINES INCLUDING BCR-ABL GENE MUTATION WITH T315I

EHA Library, Yasufumi Matsuda, 53713

GENE EXPRESSION PROFILING OF CD34+/LIN- CELLS OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AT DIAGNOSIS IDENTIFIES NEW GENES RELATED TO THE NUMBER OF CD34+/LIN- CELLS DURING NILOTINIB TREATMENT

EHA Library, Alessandra Trojani, 53714

EXPRESSION LEVELS OF CERAMIDE-GENERATING AND CLEARANCE GENES IN NEWLY DIAGNOSED AND TYROSINE KINASE INHIBITOR-RESISTANT CHRONIC MYELOID LEUKEMIA PATIENTS: AN ATTEMPT TO FIND NOVEL TARGETS

EHA Library, Melis Kartal Yandim, 53715

ANTILEUKEMIC EFFECT OF PLK INHIBITOR AND IN COMBINATION WITH ABL TYROSINE KINASE INHIBITORS AGAINST BCR-ABL-POSITIVE CELLS

EHA Library, Seiichi Okabe, 53717

TYROSINE KINASE INHIBITORS DO NOT AFFECT EXPRESSION OF DNA METHYLTRANSFERASES AND GLOBAL METHYLATION LEVEL IN CHRONIC MYELOID LEUKEMIA CELLS

EHA Library, Tomasz Stoklosa, 53719

NEW MOLECULAR MARKERS OF CML PROGRESSION

EHA Library, Vsevolod Misyurin, 53723

PROGNOSIS FOR CML PATIENTS WITH >10% BCR-ABL AFTER 3 MONTHS OF IMATINIB DEPENDS ON THE INITIAL RATE OF BCR-ABL DECLINE

EHA Library, Susan Branford, 53724

NGS-ASSISTED DNA-BASED DIGITAL QPCR FOR THE DETECTION AND QUANTIFICATION OF RESIDUAL DISEASE IN CML PATIENTS WITH UNDETECTABLE BCR-ABL1 TRANSCRIPTS

EHA Library, Alikian Mary, 53726

VERY EARLY MOLECULAR RESPONSES IN THE FIRST TWO MONTHS OF THERAPY ARE HIGHLY PREDICTIVE OF DEEP MOLECULAR RESPONSES AT 18 MONTHS, IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED UPFRONT WITH NILOTINIB.

EHA Library, Valentin Garcia-Gutierrez, 53727

THE DECLINE OF BCR-ABL/GUS RATIO IN CML PATIENTS TREATED UPFRONT WITH NILOTINIB SHOWS A RAPID DESCENT DURING THE FIRST TRIMESTER, AND THE RESPONSES ARE SIMILAR TO THOSE ACHIEVED WITH ABL AS CONTROL

EHA Library, Valentin Garcia-Gutierrez, 53728

AGE AND DIGITAL-PCR ANALYSIS PREDICT RELAPSES OF CML PATIENTS FOLLOWING PROGRAMMED IMATINIB INTERRUPTION IN Q-RT-PCR NEGATIVE CHRONIC MYELOID LEUKEMIA PATIENTS

EHA Library, Silvia Mori, 53729

EARLY RESPONSE OF RADOTINIB THERAPY MAY PREDICT LONG-TERM OUTCOMES IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH RESISTANCE OR INTOLERANCE TO BCR-ABL1 TKIS: 24 MONTH UPDATE OF PHASE 2 TRIAL

EHA Library, Sung-Hyun Kim, 53730

MR4.5 AT POST-TRANSPLANT 3 MONTHS WAS A PREDICTIVE FACTOR FOR LONG-TERM OUTCOMES IN THE PATIENTS UNDERWENT ALLOGENEIC SCT IN CML CP

EHA Library, Sung-Eun Lee, 53731

MOLECULAR MONITORING USING PERIPHERAL BLOOD COMBINED WITH BONE MARROW AT 3 MONTHS OR 6 MONTHS PROVIDES A BETTER PREDICTOR OF OUTCOMES FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA

EHA Library, Jiang Qian, 53732

BCR-ABL1 RATIO LOG REDUCTION IS A BETTER PREDICTOR OF MAJOR MOLECULAR RESPONSE (MMR) THAN 10% RATIO CUT-OFF AT 3 MONTHS IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS

EHA Library, Rafael Del Orbe Barreto, 53733

GENEXPERT BCR-ABL1/ABL1 MONITOR TEST (IS) FOR ROUTINE MONITORING OF CHRONIC MYELOID LEUKEMIA PATIENTS

EHA Library, Gueorgui Balatzenko, 53734

CHANGES OF QUALITY OF LIFE AFTER CESSATION OF IMATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH UNDETECTABLE MOLECULAR RESIDUAL DISEASE

EHA Library, Sukjoong Oh, 53737

LENALIDOMIDE MODIFIES THE BEHAVIOR OF MESENCHYMAL STROMAL CELLS (MSC) FROM PATIENTS WITH MYELODYSPLASTIC SYNDROMES WITH 5Q- (MDS-5Q-)

EHA Library, Sandra Muntion, 53739

IMPAIRED LINEAGE PRIMING AND PROLIFERATIVE POTENTIAL OF BONE MARROW MESENCHYMAL STEM CELLS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES ARE ASSOCIATED WITH ABNORMAL WNT SIGNALING PATHWAY

EHA Library, Charalampos Pontikoglou, 53740

INCREASED EXPRESSION OF INTERFERON RELATED GENES IN THE BONE MARROW MICROENVIRONMENT OF MYELODYSPLASTIC SYNDROMES

EHA Library, Miyoung Kim, 53741

CHROMOTHRIPSIS IN BONE MARROW CELLS OF ADULT PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES (MDS) WITH COMPLEX KARYOTYPES.

EHA Library, Zuzana Zemanova, 53743

CIRCULATING SERUM MICRORNA-21 PREDICTS SURVIVAL AND RESPONSE TO HYPOMETHYLATING AGENTS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Jung Yeon Lee, 53745

ANTI-ERYTHROBLAST AUTOIMMUNITY IN EARLY MYELODYSPLASTIC SYNDROMES: ENHANCEMENT OF EPO/EPO-R SYSTEM AND PRO-APOPTOTIC EFFECT

EHA Library, Anna Zaninoni, 53746

INDEPENDENT MULTICENTRIC STUDY ON THE INTEREST OF OGATA SCORE AND OF CD5, CD7 AND CD56 IN MDS AND MDS/MPS IN REAL LIFE.

EHA Library, Estelle Guerin, 53750

POSSIBLE PREVENTIVE ROLE OF CXCR4 AND ACTIVE CASPASE 3 IN LEUKEMIC EVOLUTION OF MYELODYSPLASTIC SYNDROMES

EHA Library, Veselka Nikolova, 53752

NEW GERMLINE TERT GENE MUTATIONS IN APLASTIC ANEMIA / HYPOCELLULAR MYELODYSPLASTIC SYNDROMES

EHA Library, Caterina Matteucci, 53753

IS THERE A RELATIONSHIP BETWEEN BONE MARROW CYTOMORPHOLOGY AND FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES?

EHA Library, Estelle Guerin, 53754

MOLECULAR CYTOGENETIC CHARACTERIZATION OF t(2;5)(p16.2;q33.1) LEADING TO PDGFRB/SPTBN1 GENE FUSION IN A CASE OF MDS RESPONSIVE TO IMATINIB MESYLATE

EHA Library, Daphne Koumbi, 53755

THE INTERPLAY BETWEEN OXIDATIVE STRESS AND EPIGENETIC PROFILE IN MYELOID NEOPLASIAS

EHA Library, Ana Cristina Gonçalves, 53756

IMMUNE SURVEILLANCE IMPACTS PROGNOSIS: REGULATORY T CELLS AND PROGENITOR B CELLS ARE INDEPENDENT PREDICTORS OF SURVIVAL IN LOW AND INTERMEDIATE RISK MDS

EHA Library, Josephine Kahn, 53757

DEFERASIROX CHELATION THERAPY IN TRANSFUSION DEPENDENT MDS PATIENTS. A 'REAL WORLD' REPORT FROM TWO REGIONAL ITALIAN REGISTRIES : GRUPPO ROMANO MIELODISPLASIE AND REGISTRO BASILICATA

EHA Library, Luca Maurillo, 53758

THE INCIDENCE OF COMORBIDITIES AT THE TIME OF DIAGNOSIS IN PATIENTS AFFECTED BY MYELODYSPLASTIC SYNDROMES: OVERVIEW THROUGH THE 'REL' ('RETE EMATOLOGICA LOMBARDA') DISEASE REGISTRY

EHA Library, Marta Riva, 53759

MYOCARDIAL TISSUE CHARACTERIZATION BY CARDIAC MR IMAGING IN MYELODYSPLASTIC SYNDROMES

EHA Library, Alessia Pepe, 53760

PRE AND POST-TREATMENT SERUM FERRITIN LEVELS IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES RECEIVING ERYTHROPOIESIS STIMULATING AGENTS

EHA Library, Heather Leitch, 53761

VALIDATION OF LOW RISK PROGNOSTIC SCORING SYSTEM (LR-PSS) IN 318 PATIENTS WITH LOWER RISK IPSS MYELODYSPLASTIC SYNDROME FROM A SINGLE CENTER.

EHA Library, Helena Pomares Marin, 53762

MRI SURVEY IN TRANSFUSION-DEPENDENT AND NON-TRANSFUSION-DEPENDENT MDS PATIENTS

EHA Library, Alessia Pepe, 53763

THE IMPACT OF TRANSFUSION DEPENDENCY ON THE OUTCOME OF PATIENTS WITH VERY LOW AND LOW RISK MYELODYSPLASTIC SYNDROME ACCORDING TO THE IPSS-R.

EHA Library, Montserrat Arnan, 53764

CALRETICULIN MUTATION WAS RARELY DETECTED IN PATIENTS WITH MYELODYSPLASTIC SYNDROME

EHA Library, Hsin-An Hou, 53765

DEVELOPMENT OF A HIGH RESOLUTION MELTING CURVE ANALYSIS SCREENING TEST FOR SRSF2 SPLICING FACTOR GENE MUTATIONS.

EHA Library, Eduardo Garza, 53768

GLUTATHIONE S-TRANSFERASE P1 (GSTP1) PROMOTER HYPERMETHYLATION IN MDS

EHA Library, Constantina Sambani, 53770

DAPK AND TRAIL RECEPTORS METHYLATION STATUS IN MYELODYSPLASTIC SYNDROMES PATIENTS

EHA Library, Ana Cristina Gonçalves, 53772

IDENTIFICATION OF NOVEL ALTERNATIVE SPLICE VARIANTS OF SIRTUINS IN MULTIPLE MYELOMA: A BIOLOGICALLY RELEVANT INDICATOR OF POOR OUTCOME

EHA Library, Michele Cea, 53773

BONE MARROW CD14+ CELLS SHOW DIFFERENT TRANSCRIPTIONAL PROFILES IN MULTIPLE MYELOMA (MM) AS COMPARED TO SMOLDERING MM AND MGUS: OVEREXPRESSION OF IL-21R AND ITS INVOLVEMENT IN OSTEOCLASTOGENESIS.

EHA Library, Nicola Giuliani, 53774

LONG-TERM RESULTS OF THE GIMEMA VEL-03-096 TRIAL IN MULTIPLE MYELOMA PATIENTS RECEIVING VTD CONSOLIDATION AFTER ASCT: IMPACT OF MRD KINETICS ON DURATION OF RESPONSE AND OVERALL SURVIVAL

EHA Library, Simone Ferrero, 53776

ACTIVATED AND EXPANDED NATURAL KILLER (NKAE) CELLS KILL MULTIPLE MYELOMA (MM) CLONOGENIC PLASMA CELLS THROUGH NKG2D AND NKP30 RECEPTORS AND THEIR LIGANDS

EHA Library, Alejandra Leivas, 53778

CIRCULATING MIR-34A AND MIR-130A AS BIOMARKERS OF EXTRAMEDULLARY DISEASE

EHA Library, Lenka Kubiczkova, 53779

DOES CHARACTERISTIC PHENOTYPE FOR PLASMA CELL LEUKAEMIA EXIST?

EHA Library, Lucie Rihova, 53781

GENE EXPRESSION PROFILING AND COPY NUMBER ALTERATIONS OF CIRCULATING CLONOTYPIC B CELLS OF MULTIPLE MYELOMA NEWLY DIAGNOSED PATIENTS REVEALS PATHWAYS POTENTIALLY INVOLVED IN THE DISEASE PERSISTENCE

EHA Library, Marina Martello, 53782

CAN GENOME ARRAY SCREENING REPLACE FISH AS A FRONT-LINE TEST IN MULTIPLE MYELOMA?

EHA Library, Katya Gancheva, 53783

COMPARATIVE STUDY OF GENE EXPRESSION PROFILING BETWEEN ASYMPTOMATIC AND SYMPTOMATIC WALDENSTROM\'S MACROGLOBULINEMIA PATIENTS

EHA Library, Cristina Jimenez, 53784

TRANSCRIPTIONAL REGULATION OF ALTERNATE SPLICING BY DP1 AND THEIR FUNCTIONAL IMPACT IN MULTIPLE MYELOMA

EHA Library, Mariateresa Fulciniti, 53785

DOWNREGULATION OF TELOMERASE ACTIVITY IN RESPONSE TO NEW GENERATION OF PROTEASOME INHIBITORS (EPOXOMICIN AND MG132) IN MULTIPLE MYELOMA CELLS

EHA Library, Eli Muchtar, 53786

HSP90 INHIBITOR-DRUG CONJUGATES (HDC) WITH ANTITUMOR AGENTS TARGETING HEMATOLOGICAL MALIGNANCES

EHA Library, Patricia Rao, 53787

TOLL-LIKE RECEPTOR ACTIVATION PROMOTES MULTIPLE MYELOMA CELL GROWTH AND SURVIVAL BY SUPPRESSION OF ENDOPLASMIC RETICULUM STRESS FACTOR CHOP

EHA Library, Efstathios Kastritis, 53788

ENDOPLASMIC RETICULUM STRESS-RELATED GENE EXPRESSION CAN PREDICT RESPONSE TO BORTEZOMIB IN MYELOMA

EHA Library, Narita Tomoko, 53789

MODIFYING DNA REPAIR PATHWAYS IN CHEMOTHERAPY BY GENOTOXIC DRUGS – TOWARDS PERSONALIZED MYELOMA THERAPY

EHA Library, Maria Gkotzamanidou, 53790

TARGETING ANGIOGENESIS IN MULTIPLE MYELOMA: A POSSIBLE ROLE FOR EPHA3 AND A SPECIFIC MONOCLONAL ANTIBODY

EHA Library, Antonella Caivano, 53792

INITIAL RESULTS FROM A PHASE 2 STUDY OF CARFILZOMIB, LENALIDOMIDE, AND LOW-DOSE DEXAMETHASONE (KRD) PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

EHA Library, Andrzej J. Jakubowiak, 53793

THE USE OF SINGLE AGENT ZOLEDRONIC ACID PREVENTS THE DEVELOPMENT OF BONE DISEASE COMPLICATIONS IN MYELOMA PATIENTS WITH ASYMPTOMATIC RELAPSES WITH NO DEMONSTRATED EFFECT ON SYMPTOMS PROGRESSION

EHA Library, Ramon Garcia-Sanz, 53794

LENALIDOMIDE-DEXAMETHSONE (RD) VS MELPHALAN-LENALIDOMIDE-PREDNISONE (MPR) VS CYCLOPHOSPHAMIDE-PREDNISONE-LENALIDOMIDE (CPR) IN ELDERLY COMMUNITY-BASED NEWLY DIAGNOSED MYELOMA PATIENTS

EHA Library, Valeria Magarotto, 53795

SAFETY AND EFFICACY OF DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR RELAPSED, REFRACTORY MULTIPLE MYELOMA.

EHA Library, Torben Plesner, 53796

POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE (PVD) IN LENALIDOMIDE-REFRACTORY AND PROTEASOME INHIBITOR-EXPOSED MYELOMA: THE MM-005 TRIAL

EHA Library, PAUL RICHARDSON, 53797

Preliminary pre-randomization results from a phase 3 study of front-line subcutaneous bortezomib-based induction and consolidation in transplantation-eligible multiple myeloma patients

EHA Library, Noemi Horvath, 53799

GERIATRIC ASSESSMENT PREDICTS SURVIVAL AND RISK OF SERIOUS ADVERSE EVENTS FOR ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.

EHA Library, Roberto Mina, 53800

Oral investigational proteasome inhibitor ixazomib plus lenalidomide-dexamethasone in elderly patients with previously untreated multiple myeloma

EHA Library, PAUL RICHARDSON, 53801

DOSE-DEPENDENT EFFICACY OF DARATUMUMAB AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

EHA Library, Henk Lokhorst, 53802

EFFICACY AND SAFETY OF THREE SUBCUTANEOUS BORTEZOMIB COMBINATIONS IN ELDERLY, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

EHA Library, Chiara Cerrato, 53803

RICOLINOSTAT (ACY-1215), THE FIRST SELECTIVE HISTONE DEACETYLASE 6 INHIBITOR, IS ACTIVE AND WELL TOLDERATED IN COMBINATION WITH LENALIDOMIDE OR BORTEZOMIB IN PATIENTS WITH REFRACTORY MYELOMA

EHA Library, Noopur Raje, 53804

A PHASE 2 STUDY OF CIRCULARLY PERMUTED TRAIL (CPT) PLUS THALIDOMIDE AND DEXAMETHASONE VERSUS THALIDOMIDE AND DEXAMETHASON IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

EHA Library, Wenming Chen, 53805

PRELIMINARY SAFETY AND EFFICACY OF TH-302, AN INVESTIGATIONAL HYPOXIA-TARGETED DRUG, AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RR MM)

EHA Library, PAUL RICHARDSON, 53806

POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) WITH DELETION DEL(17P) AND/OR TRANSLOCATION T(4;14).

EHA Library, Xavier Leleu, 53807

PERSISTENT PFS BENEFIT AND SUPERIOR PFS2 WITH VTD VS TD FOR NEWLY DIAGNOSED, TRANSPLANT ELIGIBLE, MULTIPLE MYELOMA (MM) PATIENTS: UPDATED ANALYSIS OF GIMEMA MMY-3006 STUDY

EHA Library, Michele Cavo, 53808

HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): THE FIRST TRIAL

EHA Library, Michel Delforge, 53809

MM-003, A PHASE 3 STUDY OF POMALIDOMIDE + LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA: OUTCOMES BY PRIOR THERAPY AND RESPONSE DEPTH

EHA Library, Jesús San Miguel, 53810

OUTCOMES OF PRIMARY SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS IN PATIENTS TREATED UPFRONT WITH BORTEZOMIB OR LENALIDOMIDE AND THE IMPORTANCE OF RISK ADAPTED STRATEGIES

EHA Library, Efstathios Kastritis, 53812

BORTEZOMIB COMBINATION THERAPY, AND SUBSEQUENT BORTEZOMIB RE-TREATMENT, IS A USEFUL TREATMENT STRATEGY FOR MULTIPLE MYELOMA PATIENTS WITH RAS MUTATIONS

EHA Library, Dean Smith, 53813

EUROPEAN POST-APPROVAL SAFETY STUDY (PASS) OF RELAPSE/REFRACTORY MULTIPLE MYELOMA (RRMM): PATTERNS OF ANTITHROMBOTIC PROPHYLAXIS IN A LARGE COHORT OF MM PATIENTS TREATED WITH LENALIDOMIDE

EHA Library, Barbara Gamberi, 53814

Long-term follow-up of a randomized phase 2 study of bortezomib, thalidomide, and dexamethasone, with or without cyclophosphamide, as induction therapy for patients with previously untreated multiple myeloma

EHA Library, Heinz Ludwig, 53815

A PHASE 1 STUDY OF FILANESIB (ARRY-520) WITH BORTEZOMIB (BTZ) AND DEXAMETHASONE (DEX) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Ajai Chari, 53816

A PHASE IB DOSE ESCALATION TRIAL OF SAR650984 (ANTI-CD-38 MAB) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Thomas Martin, 53819

Monoclonal gammopathy of undetermined significance is associated with inferior survival: a population-based study

EHA Library, Ebba Lindqvist, 53821

INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Kai Riecke, 53822

MULTIPLE MYELOMA PATIENTS THAT DEVELOP SECOND PRIMARY MALIGNANCY HAVE A WORSE PROGNOSIS THAN MULTIPLE MYELOMA PATIENTS TREATED BEFORE THE INTRODUCTION OF NOVEL AGENTS: A POPULATION BASED-STUDY

EHA Library, Gudbjörg Jónsdóttir, 53824